News

The randomized, double-blind, placebo-controlled, multi-center study will have the primary objective of demonstrating the superiority of NRD135S.E1 over placebo in relieving PDPN in patients after 3 months of

The French vaccines company, which is part of Sanofi, signed a collaboration and license agreement deal worth up to $805m with Translate Bio in 2018 for developing mRNA

Frontier Scientific identified and developed multiple synthetic processes to produce stannous protoporphyrin (SnPP) – the active pharmaceutical ingredient of RBT-9, an investigational drug entering a Phase 2 trial

The deal also provides Gilead with an exclusive option to acquire the remaining stake in Pionyr for around $315m. The shareholders of Pionyr will secure up to an

The QINLOCK New Drug Submission was approved by Health Canada under Project Orbis, an initiative of the U.S. Food and Drug Administration’s (FDA) Oncology Center of Excellence designed

Both the late-stage trials – PNEU-WAY and PNEU-FLU evaluated the safety, tolerability, and immunogenicity of V114, said Merck. The investigational vaccine is being developed for the prevention of

In May, Gilead Sciences secured emergency use authorisation (EUA) from the US Food and Drug Administration (FDA) for its remdesivir to treat of hospitalised Covid-19 patients. Remdesivir is

The transaction closure is subject to customary pre-closing conditions. According to the terms of the agreement, PEL, through one of its Affiliates, would acquire at closing a 100%

Following the approval from the drug regulator, Glenmark Pharmaceuticals has launched the generic version of oral antiviral drug Favipiravir under the brand name of FabiFlu. Favipiravir was developed